kumc.edu
Aug 6, 2025, 11:28
Al-Ola A Abdallah: The Current State of TIL Therapy in Metastatic Melanoma Presented by Muhammad Umair Mushtaq
Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on X:
“At the 2025 National Immune Cell Effector Therapy ICE_T conference, Muhammad Umair Mushtaq (Abu Mikael) presented on the current state of tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma with Cancer Netwrk: At 4 years, about 20% of patients with advanced melanoma who received TIL therapy were alive and responding to treatment.”
More posts featuring Al-Ola A Abdallah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 16, 2025, 21:51
Aug 16, 2025, 21:38
Aug 16, 2025, 21:05
Aug 16, 2025, 20:40
Aug 16, 2025, 20:27
Aug 16, 2025, 20:22